NASDAQ:ORMP Oramed Pharmaceuticals Q2 2025 Earnings Results & Report $4.22 +0.05 (+1.20%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more. Oramed Pharmaceuticals missed analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.05 versus the -$0.04 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call8:00 AM ET Oramed Pharmaceuticals EPS ResultsActual EPS-$0.05Consensus EPS -$0.04Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersOramed Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsOramed Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Oramed Pharmaceuticals Q2 2025 Earnings FAQ Did Oramed Pharmaceuticals beat earnings estimates for Q2 2025? Oramed Pharmaceuticals (NASDAQ:ORMP) reported earnings of -$0.05 per share for Q2 2025, missing the consensus estimate of -$0.04. The report was announced on Thursday, August 14, 2025. When is Oramed Pharmaceuticals' next earnings date? Oramed Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Oramed Pharmaceuticals on the company's earnings history page. Oramed Pharmaceuticals Earnings HeadlinesFinancial Contrast: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)October 8, 2026 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) COO Joshua Hexter Sells 30,000 Shares of StockOctober 3, 2026 | americanbankingnews.comThe Midwestern Disruptor Big Pharma Doesn’t Want You to Know AboutA little-known Midwestern firm sits at the center of what the Wall Street Journal calls medicine's biggest moment since antibiotics. It does not invent drugs or hold blockbuster patents. McKinsey calls the shift a game changer, and the International Journal of Surgery describes it as a revolutionary path forward. Yet this company remains largely overlooked by investors. See the full research on this emerging healthcare story now.October 14 at 1:00 AM | Compounding Quality (Ad)Oramed Pharmaceuticals consensus price target increased 12.00% to $7.14September 15, 2026 | msn.comOramed: Q2 Earnings SnapshotAugust 11, 2026 | chron.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comSee More Oramed Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email. Email Address About Oramed PharmaceuticalsOramed Pharmaceuticals (NASDAQ:ORMP) is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream. The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies. Oramed has evaluated its candidates in clinical studies involving patients with diabetes and has also pursued partnerships and licensing opportunities to advance its oral drug-delivery platform. Founded in 2006, Oramed is headquartered in Jerusalem, Israel, and has maintained corporate operations in the United States. Nadav Kidron has served as the company’s chief executive officer, while Professor Miriam Kidron, one of the company’s founders, has been associated with its scientific leadership. The company’s shares trade on the Nasdaq Capital Market under the symbol ORMP.View Oramed Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
